– USA, CO – TriSalus Life Sciences Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors, announced the appointments of William Valle and Dr. Gary Gordon (M.D., Ph.D.) to its Board of Directors, effective as of January 29, 2025.
“We are thrilled to welcome William Valle and Dr. Gary Gordon to our Board,” said Board Chairman, Mats Wahlstrom. “Bill brings exceptional expertise in medical device commercialization and reimbursement, honed over a distinguished career with Fresenius, while Gary is a visionary in oncology drug development, having helped to establish AbbVie’s oncology franchise and guide a multibillion dollar oncology program to regulatory approval over the past 25 years. Together, they bring complementary insights into the medical device and oncology landscapes, which will be instrumental in advancing our mission. We look forward to their leadership and the invaluable perspectives they bring to TriSalus.”
About William J. Valle
William Valle most recently served as CEO of North America at Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from 2017 to 2023. He was also a member of the Company’s Management Board. Before this role, Mr. Valle served as EVP and President of Fresenius Kidney Care at Fresenius Medical Care Holdings, Inc. He previously held key leadership positions at Fresenius, including EVP of Fresenius Medical Services (FMCNA) and President of Fresenius Medical Services (FMS), where he oversaw the management of over 2,400 outpatient facilities, 1,400 inpatient programs, and 800 home dialysis programs across the U.S. serving approximately 187,000 dialysis patients.
As President of Fresenius Medical Care Integrated Renal Services, Mr. Valle led the integration of several critical business functions, including Fresenius Vascular Care, FreseniusRx, Spectra Laboratories, FMS Business Development, FMS Inpatient Services and FMS Real Estate and Construction Services into a high performing renal network focused on improving patient outcomes and reducing the cost of renal disease management. With 22 years of experience in the dialysis industry, holding executive positions at several dialysis companies including Gambro Healthcare, Inc., he serves as Director at Fresenius Medical Care US Finance II, Inc.
“TriSalus’ technology with its Pressure-Enabled Drug Delivery method represents a disruptive innovation in drug delivery, offering transformative potential in the ability to improve therapeutic delivery to solid tumors,” said William Valle. “I’m excited to collaborate with Mats, Gary, and the rest of the Board to unlock the full potential of this innovative technology.”
About Dr. Gary B. Gordon
Dr. Gary B. Gordon is an accomplished pharmaceutical executive and strategic business leader with a proven track record in drug development, spanning from first-in-human studies to approval and commercialization. Since 2018, Dr. Gordon has been a member of the Global Coalition of Adaptive Research (GCAR), an organization that brings together physicians, clinical researchers, advocacy groups, biotech and pharma companies, health authorities, and other healthcare stakeholders to accelerate the discovery and development of treatments for rare and life-threatening diseases.
Previously, Dr. Gordon served as VP of the Oncology Department at AbbVie, where he played a pivotal role in developing AbbVie’s oncology franchise, driving its expansion and solidifying the Company’s leadership in oncology. His work included overseeing the approval of venetoclax, leading major acquisitions, and fostering critical collaborations. He was also part of the AbbVie-Genentech team that received the 2017 Prix Galien Award for Best Pharmaceutical Product.
“The TriSalus Pancreatic Retrograde Venous Infusion System, designed to deliver high concentrations of therapeutics directly to the pancreatic tumor site, offers a promising potential solution to the significant challenges of treating pancreatic cancer,” said Dr. Gary Gordon. “I am excited to collaborate with Bill, the Board, and the leadership team to advance the integration of this technology with nelitolimod and other therapeutic approaches, driving toward potentially better outcomes for patients facing this difficult-to-treat disease.”
Before his time at AbbVie, Dr. Gary Gordon was CSO and VP of Clinical Affairs at Ovation Pharmaceuticals from 2001 to 2003. He began his pharmaceutical career in 1995 with the G.D. Searle division of Monsanto, which later became part of Pharmacia.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology-focused medical technology business providing disruptive drug delivery technology to improve therapeutic delivery to solid tumors. The Company’s platform includes devices with a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors as well as other solid tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of infusion into solid tumors. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to limit delivery to normal tissue, creating the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
For more: https://trisaluslifesci.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.